Stallergenes Greer Foundation Science Awards for Allergy 2023: Call for Applications
8.6.2023 11:00:00 EEST | Business Wire | Press release
The Stallergenes Greer Foundation aims to create healthier futures for all. The Foundation, under the aegis of the Fondation de France, is philanthropically dedicated to three focus areas:
- Advancing scientific research to bolster innovation and precision medicine.
- Supporting academic initiatives to further develop future generations of allergy healthcare professionals.
- Engaging in climate action and environmental protection to progress the prevention and treatment of allergies.
Submissions are open for the Stallergenes Greer Foundation Science Awards for Allergy 2023. A total of €150,000 will be awarded for outstanding work led either by a young scientist or a mid-career scientist to advance precision medicine in the field of allergy, or outstanding work in the environmental field to advance the prevention and treatment of allergies.
The Stallergenes Greer Foundation Science Awards for Allergy are presented in two areas:
- Innovation Awards: two awards will be presented either to encourage and raise the profile of a young scientist (below 40 years of age) or to recognise the outstanding work of a mid-career scientist (with a 10–20-year track record), who are driving innovation in respiratory and food allergy.
- Environmental Health Award: the award will honour the work of a researcher who is pioneering research aimed at preserving and restoring both natural and built ecosystems and contributing to advancing the prevention and treatment of allergies.
Timeline: The submission period is open from July 1, 2023, to November 29, 2023, at 11:59pm CET. Submissions will be reviewed by the Stallergenes Greer Foundation’s Board of Trustees. Decision letters will be sent out at the end of February 2024.
Eligibility: the awards are open to physicians, PhDs and Pharm-Ds actively engaged in allergy research and attached to a research team in a non-profit research laboratory. There are no geographic limitations.
Rules and regulations: Detailed guidelines regarding the Stallergenes Greer Foundation’s Science Awards for Allergy are available on the foundation’s website: https://stallergenesgreer-foundation.org
About the Stallergenes Greer Foundation
The Stallergenes Greer Foundation, under the aegis of the Fondation de France, is a non-profit foundation whose aim is to build healthier futures for all. The Stallergenes Greer Foundation pursues a comprehensive approach calling for “the collaborative efforts of multiple disciplines working locally, nationally, and globally, to attain optimal health for people, animals and our environment”, as defined by the One Health initiative.
About the Fondation de France
Created in 1969, Fondation de France is a private organisation recognised of public interest, whose mission is to support all forms of generosity and translate them into effective actions of general interest. With close to 1,000 hosted foundations, the Fondation de France supports more than 10,000 promising and innovative initiatives each year, in France and abroad. Independent and private, it operates thanks to the generosity of donors.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005058/en/
Contact information
Stallergenes Greer Foundation
Catherine Kress
Secretary General
Tel: +33 (0)1 55 50 26 05
Email: catherine.kress@stallergenesgreer.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ABB Extends Engagement with Wipro to Deliver and Enhance Global Digital Workplace Services2.9.2026 16:30:00 EEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading AI-powered technology services and consulting company, has renewed its long-standing Digital Workplace Services contract with ABB, a global technology leader in electrification and automation. Building on an established relationship spanning multiple years, Wipro will continue delivering end-to-end AI-enabled Digital Workplace Services for ABB's global operations while further enhancing employee experience through advanced automation, AI-powered service capabilities, and workplace modernization initiatives. Powered by Wipro Intelligence™, the unified suite of AI platforms, solutions and transformative offerings, this engagement will modernize ABB’s digital workplace with AI-led, experience-centric capabilities delivered through Wipro’s AI Live Workspace™ and Digital Workplace Services offerings and operationalized through WINGS, Wipro’s AI-powered delivery platform for operations. Through SmartOps, Wipro’s AIOps capability,
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 16:00:00 EEST | Press release
Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software. "Almost every organization we speak to is trying to get its data ready for AI, and most of them are realizing that the hard part is not the model, it is the da
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 16:00:00 EEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom